Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The important bits and pieces of NanoViricides, Inc. PRs...
NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide(TM) , in a Non-GLP Study
As previously reported, the results of this study will provide both the basis and focus for the GLP safety and toxicology studies of FluCide that are required for the IND submission to the U.S. FDA. These GLP studies will be performed on both large and small animals at the BASi facility in Indiana.
We are currently focusing on advancing our Injectable FluCide™ drug, for the treatment of severely ill, hospitalized, influenza patients, towards an IND filing. We have also developed an Oral FluCide drug that continues to advance following the injectable version. Both of our FluCide drug candidates are “broad-spectrum”, i.e. they are expected to be able to combat most, if not all, influenza viruses, including bird flu, high path influenzas, epidemic influenzas, seasonal influenzas, and potentially any novel influenza A strains.
The Company is scaling up the production of FluCide from gram scale to several hundred grams scale. The Company believes that the scale up and reproducibility of product batches can be effectively controlled.
If toxic Marijuana is getting licensed in states without a challenge from the Department of Justice, low-toxicity and life-saving NanoViricides, Inc. FluCide should find its way to market and soon. NanoViricides, Inc. is in a race to market. They are frugal and spend their money judiciously. Remarkable news are forthcoming.
How long do drugs stay in your system? How long will FluCide? A week, two weeks?
Vertex Pharmaceuticals suffered a meaningful setback 2013 in its bid to remain a long-term player in the treatment of hepatitis C.
The Cambridge, MA-based biotech company (NASDAQ: VRTX) said that the FDA has stopped the company from giving certain doses of its VX-135 drug candidate for hepatitis C in a mid-stage U.S. study, after seeing evidence of liver toxicity in patients in Europe. The FDA put a hold on Vertex’ plans to deliver 200-milligram doses of VX-135 in the U.S., but has allowed the study to continue enrolling patients on a lower, 100 milligram dose.
The world's most dangerous Virus
Viruses are supposed to be the biological weapons of the future.They are everywhere. Millions of viruses around us, interact, invade. Virus able to evolve, change your environment, jump from one species to another. Scientists continue its track. Looking hiding in nature, in animals that viruses use to travel from one place to another planet ... but not always find them.
In recent decades there have been many diseases that so far only affected animals. These diseases, caused by very aggressive virus, appear with high frequency in Africa, and requires a high financial contribution in order to eradicate them. Marburg virus, influenza, dengue, yellow fever, Ebola virus, human immunodeficiency virus, Epstein-Barr...
To find answers we enter for the first time in the High Security Center Biological where the most dangerous viruses in history and the emerging service. And the World Health Organization explains how he manages to monitor the emergence of new viruses and diseases in any country.
In the past year (2013), NanoViricides, Inc. (the Company) has focused on three important objectives:
1. Advanced Pre-clinical development of our Injectable FluCide towards IND filing;
2. Enabling a highly customizable pilot-scale cGMP manufacturing capability for the production of clinical study quantities of any of its nanoviricides® drug candidates and any of the various formulations of these candidates;
3. Improving Corporate Governance towards up-listing the Company on a national exchange.
The Company reported that it has been successful in advancing each of these objectives. On September 25, 2013, the Company stock was listed and began trading on the NYSE MKT national exchange.
The Company has signed a Memorandum of Understanding (MOU) with Inno-Haven, LLC, for the total renovation of the 1 Controls Drive, Shelton, CT, facility purchased by Inno-Haven into a pilot scale cGMP facility and associated R&D laboratory space. Inno-Haven is controlled by Anil R. Diwan, PhD, our founder. Inno-Haven has raised substantial amount of capital for this project through various sources, and it is expected that they will be able to raise all of the necessary funding for this project, with minimal capital expenses to be borne by NanoViricides, Inc. The Company is expected to lease the facility. The terms of the lease are expected to be negotiated after the total cost of the facility can be determined to a substantial extent. No lease has been signed yet. The project is already in construction phase, and is anticipated to be completed in the first calendar quarter of 2014, if no additional delays such as long lead times or back orders on equipment etc. are encountered.
We are currently focusing on advancing our Injectable FluCide™ drug, for the treatment of severely ill, hospitalized, influenza patients, towards an IND filing. We have also developed an Oral FluCide drug that continues to advance following the injectable version. Both of our FluCide drug candidates are “broad-spectrum”, i.e. they are expected to be able to combat most, if not all, influenza viruses, including bird flu, high path influenzas, epidemic influenzas, seasonal influenzas, and potentially any novel influenza A strains.
The Company is scaling up the production of FluCide from gram scale to several hundred grams scale. The Company believes that the scale up and reproducibility of product batches can be effectively controlled.
source: http://www.nanoviricides.com/press%20releases/2013/NanoViricides%20Files%20Annual%20Report%20-%20Reports%20Having%20Sufficient%20Funds%20to%20Advance%20A%20Drug%20Candidate%20into%20Clinical%20Trials.html
We are moving forward on the (3) objectives and we are waiting for PRs that describe how well we are progressing with BASi GLP Toxicology and Safety Studies on the FluCide candidate, among others! The first Monday of 2014 is fast aproaching! IMHO, it will be an epic NanoViricides, Inc. 2014!
Pharmacokinetics made simple
Wishing all a great "NanoViricides, Inc." (NNVC) NEW YEAR (2014)!
I think it is safe to say that if you, among others, toured the facility, the walls of the facility are all integrated. I do not know if FDA will give its stamp of approval on every stage of the cGMP Pilot Plant...??? Next? Moving the equipment into the facility as soon as it arrives at the premises. Then get the equipment/instruments humming to produce (3) identical batches of the FluCide candidate. The FDA will give its stamp of approval at this stage.
I hope GLP tox studies preliminary results will prompt NanoViricides, Inc. to request "Breakthrough Therapy designation". That will be another PR as we get "Fast tracked".
Have a merry Christmas and a happy new year!
drkazmd65, I am hoping that as preliminary reports, or PRs, on BASi GLP tox studies start to come out it will send pps higher (1Q 2014). Couple that with more news on progress towards human trials (cGMP plant commissioned). To aid this pps movement higher we should all post comments on articles, published on the web, about menacing viruses. These comments could simply be excerpts from Nanoviricides, Inc. PRs that includes a link to Nanoviricides.com. Recently, leifsmith gave an example --- see http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94976304. We could also place a link to the best posts on this board.
Best to all on this holiday season!
Hear, hear!
The interview was less than 15 minutes and in my opinion was an attempt to reach new investors that listen to Micha Yorba radio show. There was nothing new to those that post or read messages on the NNVC board. Investors that tune in to the radio show got the company name, symbol NNVC and what in essence the company is doing with their "breakthrough technology". Potential new investors also know how to search for more information.
Announcement by next Monday, or before the end of the year, that a new GMP 5 kg pilot facility is completely integrated (not commissioned), would be nice.
By the way, is that Woody Allen, in your signature image, playing the clarinet?
Advance video to 07:48 min...I'm a clarinet player...
In Vivo Pharmacokinetic and Pharmacodynamic Studies for nanomedicines on cancer. How different are these nanomedicine studies from studies for nanoviricides in a host?
Pharmacokinetics/pharmacodynamics (PK/PD): Data collected at multiple timepoints after the administration of a nanomedicine in animal models allows for a complete pharmacokinetic and pharmacodynamic analysis of the nano agent in vivo. PK/PD assessments are performed using WinNonlin data management, a statistics, modeling, and visualization tool for PK data analysis. Parameters typically provided for a given nanomedicine include drug concentration over time, area under the curve (AUC), elimination half life, clearance, and time of maximum concentration.
Hey ZincFinger, excellent and thorough explanation of facts! Thank you. Do you think these people would accept NanoViricides, Inc. candidate, DengueCide, on a separate track within their database? Then at any given time they could list all drugs candidates that interact with the body and then a separate list of one candidate, that does not interact with the body, from NanoViricides, Inc., DengueCide. Just a thought.
How about one song that is more cheering and a tune with the season...
Drugs that interact with your body vs. drugs that are agnostic to the host, like NanoViricides, Inc. DengueCide and FluCide. Indeed a waste of money.
Discovering Dengue Drugs-Together
The mission of this project is to identify drug leads with broad spectrum activity against the related dengue, hepatitis C, West Nile, and yellow fever viruses. The extensive computing power of World Community Grid will be used to complete the structure-based drug discovery calculations required to identify promising drug leads.
Viruses from the family Flaviviridae, such as dengue (DENV), hepatitis C (HCV), West Nile (WNV), and yellow fever (YFV) viruses, pose significant health threats throughout the developed and developing world. More than 40% of the world’s population is at risk for infection by DENV. Annually, 1.5 million people are treated for dengue fever and dengue hemorrhagic fever. In addition, ~2% of the world’s population is infected with HCV. Yellow fever and West Nile viruses have also had significant global impact. Unfortunately, there are no drugs that effectively treat these diseases.
One promising approach to combat these diseases is to develop drugs that inhibit the viral protease. This enzyme is critical for virus replication and is highly conserved among different flaviviruses. We have already made significant progress, having successfully identified compounds that simultaneously inhibit DENV and WNV proteases and prevent virus replication in cell culture. However, additional drug candidates need to be discovered to improve the likelihood of converting drug leads into approved drugs for treating flavivirus infections.
The computing power of World Community Grid will be harnessed to complete calculations that will identify new compounds that bind tightly to flavivirus proteases, and terminate DENV, HCV, WNV, and YFV replication. Normally, these calculations require thousands of years of computer time. However, the combined power of World Community Grid computers will enable this project to be completed within 9-12 months.
Identifying new compounds that broadly inhibit dengue, hepatitis C, West Nile, and yellow fever viruses is a significant step in our quest to change the world by dramatically improving global health.
source: http://www.utmb.edu/discoveringdenguedrugs-together/
I have read some good notes from many that post on this board but your compilation of notes are some of the most...
$1000 pps within 7 years once the "railway to market", with DengueCide and Flucide, is built. All the other drugs will follow in quick succession.
The cGMP pilot plant, to be completed in 2014) is highly customizable and NanoViricides Inc. has 4.2 acres (less 18,000 sq. ft. facility) to develop.
Read more here...http://online.wsj.com/article/PR-CO-20131211-906488.html?dsk=y
Have a great day!
Under $10 and Set to Soar - NanoViricides, Inc. (NNVC)
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
source: http://www.thestreet.com/story/12132123/4/5-stocks-under-10-set-to-soar.html
Let it rip!
Good Monday news from NanoViricides, Inc.
NanoViricides, Inc. Reports Excellent Safety Profile of Its Broad-Spectrum anti-Influenza Drug Candidate, FluCide(TM) , in a Non-GLP Study
Business Wire via CMTX
http://www.barchart.com/headlines/story/1519699/nanoviricides-inc-reports-excellent-safety-profile-of-its-broad-spectrum-anti-influenza-drug-candidate-flucide-tm-in-a-non-glp-study
Remember this post? http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92935215
The following is from FDA's "Father of GLP":
Good editing. The author of the article did take some license with words. I would suggest to all posters on this board to follow the link(s) to these kinds of articles and post a comment with a clarification followed by links to 1-5 of the best posts IH/NNVC board on the particular virus. Those looking for answers could become buyersof NNVC shares.
From drkazmd65 post: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91529236
Have your powder dry/ready and comment away!
While we wait for the cure, DengueCide from NanoViricides, Inc...
Its simple and effective. Get Cure from Dengue Fever in 1 day with Papaya leaf juice. Chymopapin and papin – enzymes in the papaya leaf – help revive platelet count, say experts.
The juice of the humble papaya leaf has been seen to arrest the destruction of platelets that has been the cause for so many deaths this dengue season. Researchers have found that enzymes in the papaya leaf can fight a host of viral infections, not just dengue, and can help regenerate platelets and white blood cells.
Scores of patients have benefited from the papaya leaf juice, say doctors.
Papaya has always been known to be good for the digestive system. Due to its rich vitamin and mineral content, it is a health freak’s favorite. But its dengue -fighting properties have only recently been discovered.
Procedure
Accordingly it is raw papaya leaves, 2pcs just cleaned and pound and squeeze with filter cloth. You will only get one tablespoon per leaf. So two tablespoon per serving once a day. Do not boil or cook or rinse with hot water, it will loose its strength. Only the leafy part and no stem or sap. You have to swallow Papaya Juice – Cure for Dengue... Papaya juice is a natural cure for dengue fever.
http://www.curacaochronicle.com/health/dengue-fever-remedy-using-papaya-fruitleaves/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614241/
The first time I read about NanoViricides, Inc., I was mesmerized. Now, I am a bit anxious but then I read about NanoViricides, Inc. associations with prominent companies/collaborators and my mind is set more at ease.
I figure the WHO, CDC will have a sound strategy to distribute nanoviricides, as close to the source as possible, and points of entry to their respective countries. We also will have protection at hand. NanoViricides, Inc. will be here and in every country that has agreed to protect NanoViricides, Inc. IP.
Thanks for expanding on this. I read what you write with great interest. I have also read a reply from the BigKahuna which is similar to a post I had seen before, sometime ago.
What is the link to the webpage?
Thanks for the clarification ZincFinger.
Between your $2000 pps and my $200 pps there is no contest. You win hands down!
I would say ask a tax deductible donation, from private western/world banks, or better, have them wave the compound interest on the national debt for a year. It would be their gift to the world. That should take care of the expense in saving lives. Imagine all that positive promotion for elitist bankers! Do these world banks ever pay taxes?
Now, NNVC could reach market rather quickly if Big Pharma were to create another world flu scare.
http://letstalkbooksandpolitics.blogspot.com/2011/04/troubling-tale-of-tamiflu-and-drug.html
The quote came from stock gumshoe. It may be one of the first quotes from Patrick Cox however I like most of the quote and that is why I re-posted it. Have a great day!
I think you and many here will agree we are in the business of doing both, a killing once FluCide gets approved to market by FDA and free millions from the threat of a human killing virus.
I don't have a "reasonable" profit in mind but I have "unreasonable,...$200 pps 4Q 2014. However, I will be happy with a $100 pps as likely the majority of this board would be.
Best to you and all NNVC investors,...that includes me!
I am definitely looking forward to those consecutive days of 10 to 25% climb in pps, followed by a few days of accumulation. A 200 pps sounds very good. How soon? Next year? I know, that sounds so off the "beaten path" for the average a "transformational technology" company. It is going to be up, up and away!
Bullish! The steady hands and indomitable spirit of NanoViricides, Inc. investors, higher with low volume...Monday on higher volume!
We've had a couple of consecutive weeks with DengueCide news. I would not be surprised if next Monday, the news on FluCide begin. Borrowing from ZincFinger's post/observations, "NNVC's remarkable and solid progress in last 6 months" has been nothing short of that, remarkable.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=93337684
We are due for good news on FluCide progress and another solid move upwards on the main attraction, FluCide.
NNVC may very well reverse the downward trend tomorrow, close with a higher-low and end green for the week. Friday green and then Monday,...